Under the policy change, Aetna will give medical necessity designation to noninvasive prenatal testing that measures cell-free fetal nucleic acids in maternal blood. The testing is used to screen for fetal aneuploidy, a condition that occurs when a fetus has one or more extra or missing chromosomes.
The coverage change falls in line with other national payers like UnitedHealthcare and Humana, who recently began covering noninvasive prenatal testing for average-risk pregnancies, according to GenomeWeb.
More articles on payers:
Radiologists to Cigna: Revise hospital-based imaging policy to avoid harming pediatric patients
UnitedHealth expects $277B+ in revenue in 2021
New Jersey school board sues Horizon, says insurer threatened to stop paying claims for 14,000 workers
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
